HRT Financial’s Elicio Therapeutics ELTX Stock Holding History

HRT Financial’s Portfolio ELTX Stock Details ELTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-21,611	Closed	-$231K	–	4515
2026 Q1	$231K	Buy	+21,611	New	+$209K	﹤0.01%	3096
2021 Q3	–	Sell	-5,986	Closed	-$779K	–	3406
2021 Q2	$779K	Buy	+5,986	New	+$863K	0.01%	1307

Other funds holding ELTX

KCM

Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

HRT Financial's ELTX Position: Q2 2026 in Review

HRT Financial sold out of Elicio Therapeutics (ELTX) in Q2 2026, closing a stake of 21,611 shares — an estimated $231K sold.

HRT Financial first reported a position in ELTX in Q2 2021 and held it in 2 quarters. The position peaked at $779K in Q2 2021. 48 funds tracked by Wall St. Rank hold ELTX as of Q2 2026.

HRT Financial reported no remaining Elicio Therapeutics position as of Q2 2026 after selling out during the quarter.
HRT Financial sold 21,611 Elicio Therapeutics shares in Q2 2026, an estimated $231K.
HRT Financial first reported a position in Elicio Therapeutics in Q2 2021 and held it in 2 quarters.
HRT Financial's Elicio Therapeutics position peaked at $779K in Q2 2021.
48 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.